

Next steps for Evidence Dissemination

Patrick Ryan, Martijn Schuemie, Nicole Pratt



Scaling evidence together

Current status quo:

One Person from **One Institution** has One Question about One Exposure and One Outcome applies One Design to One Database generating **One Result** disseminated in **One Publication** to communicate to **One Audience** Future reality:

One Community of 1000s of persons from Many Institutions have An Array Of Questions about All Exposures and All Outcomes applies Standardized Framework **Incorporating Multiple Designs** to A Network of 100s of Databases Generating Millions of Results disseminated across Multiple Channels To maximize the reach and impact across stakeholders



Reflecting on the Journey So Far

Initial OHDSI vision:

"OHDSI collaborators access a network of 1 billion patients to generate evidence about all aspects of healthcare. Patients and clinicians and other decisionmakers around the world use OHDSI tools and evidence every day"

2017

Dec

2013

2015

2014

2016

OHDSI vision revised:

2018

2019

"A world in which observational research produces a comprehensive understanding of health and disease."

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

2020

2021

2022

2023

2024


Oct

2024

•••



What is the Journey Ahead Together?






How much do you agree that by 2034, we will achieve the following prediction:



OHDSI's open science community approach to evidence generation becomes the expected behavior across stakeholders and disciplines to promote innovation, reproducibility, and collaboration.





OHDSI's open science community approach to evidence generation becomes the expected behavior across stakeholders and disciplines to promote innovation, reproducibility, and collaboration.

The OMOP Common Data Model will evolve and become recognized as the preferred international data standard for real-world evidence generation, will be seamlessly interoperable with complementary clinical data exchange standards, and will be consistently adopted across academia, industry, and government around the world.

The number of unique data sources adopting the OMOP CDM will exceed 50,000, but organizations will also use the CDM as a mechanism to partner to advance crossorganizational data linkage and participatory patient self-reporting. This will increase the completeness and longitudinal continuity of patient records, enable connections across familial generations, and improve the fitnessof-use for each integrated source across a broader set of analytic use cases.



The OHDSI Standardized Vocabularies will provide the singular resource that maps all source terminologies and unstructured medical text into a common reference ontology, with real-time updating to reflect the current state of knowledge in medicine.



Every organization collecting patientlevel data during the routine course of clinical care will have established systems to standardize the data to the **OMOP CDM using the latest OHDSI** standardized vocabularies on a nightly basis, enabling daily reporting for disease surveillance and quality improvement.

The OHDSI community will prove that real world evidence from real world data --- when adhering OHDSI's best practices and passing all objective diagnostics—can be considered just as reliable as evidence from randomized clinical trials. Open-source systems that follow these practices will become trusted by health systems, payers, and regulators for guiding clinical care and policy decisions.



Advances in OHDSI's open-source analytic platform will decrease the time to generate reliable real-world evidence across the OHDSI distributed network; this process will be measured in minutes, not months.



The OHDSI Evidence Network will make it both commonplace and expected to see hundreds of databases, representing hundreds of millions of patients, be represented in network studies of every important public health question. This would ensure that the evidence we generate is replicable within similar populations and generalizable to patients across North and South America, Europe, Africa, Asia and Australia.



The OHDSI community will represent and support all clinical subspecialties and will become the primary source of real-world evidence to proactively fill evidence gaps needed to inform clinical guidelines around management of every disease.



The OHDSI community will design, implement, and deliver results from more than 10,000 network studies, with the majority of research questions coming directly from patients and clinicians seeking reliable evidence to address their needs at the point-of-care.



Discoveries across the OHDSI network about unrecognized effects of existing medical interventions will yield new indications that achieve regulatory approval due to the robustness of the real-world evidence produced within our community.



OHDSI will freely disseminate its evidence through more than 100,000 scholarly publications, but it will also establish new modalities for evidence dissemination to more directly support clinical practice.



Every disease will have a comprehensive real-world evidence summary that characterizes natural history and treatment pathways across the globe so we can understand patient heterogeneity, promote health equity, and recognize unmet medical needs.



Every medical product will have a comprehensive real-world evidence surveillance summary from OHDSI that provides characterization of the incidence of all outcomes, population-level estimation of the causally attributable risk of each outcome and comparative effectiveness with all alternative treatments, and patient-level prediction models so that individuals can accurately determine their personalized risk given their medical history.




OHDSI evidence repositories will become the primary source of knowledge underpinning foundational models to promote better health decisions and better care.





Pre-specification of a systematic approach

Traditional observational study:





A rubric for interpreting studies

- Quality of study
 - Study design
 - Multiple designs to evaluate robustness (ex: comparative cohort and SCCS)
 - Multiple analyses within design (ex: PS matching vs stratification, on-treatment vs. ITT)
 - Objective diagnostics to test statistical assumptions, quantify residual error, and establish unblinding rules
 - Transparency
 - Pre-specified protocol
 - Publicly accessible analytic source code
 - Provenance of full resultset
 - Diversity of databases
 - Populations
 - Geographies
 - Data capture processes



A rubric for interpreting studies

- Strength of evidence
 - Continuum:
 - No evidence: No databases pass diagnostics
 - Weak: One database pass diagnostics, lots of databases fail
 - Strong: lots of diverse databases pass and few fail diagnostic (including diagnostic for heterogeneity)
- Certainty in estimate
- Size of effect



What you need to collaborate on evidence at scale

+ Calibrated estimate

LEGEND-T2DM Evidence Dissemination Summary

- Target (class): Semaglutide (GLP-1 Receptor Agonists)
- · Comparator (class): Glimepiride (Sulfonylureas)
- Outcome: Acute pancreatitis

How Often? (Incidence rates in the PS-matched target cohorts)


Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	99,708	52,939	60	1.13
Merative CCAE	20,240	9,388	14	1.49
Merative MDCD	-	-	-	-
Merative MDCR	619	278	<5	<17.97
Optum Clinformatics	7,607	3,811	8	2.10
Optum EHR	6,717	2,098	7	3.34
Veterans Affairs	1.258	883	-	0.00


How Reliable Are the Effect Estimates? (Objective diagnostics)

Comparator Target Before After MDRR • Negative control

IQVIA DA Germany

IQVIA LDP France









Database diagnostics


LEGEND-T2DM Evidence Dissemination Summary

- Target (class): Semaglutide (GLP-1 Receptor Agonists)
- Comparator (class): Glimepiride (Sulfonylureas)
- Outcome: Acute pancreatitis

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	
IQVIA Open Claims	99,708	52,939	60	1.13
Merative CCAE	20,240	9,388	14	1.49
Merative MDCD	-	-	-	
Merative MDCR	619	278	<5	<17.97
Optum Clinformatics	7,607	3,811	8	2.10
Optum EHR	6,717	2,098	7	3.34
Veterans Affairs	1 258	883	-	0.00

How Reliable Are the Effect Estimates? (Objective diagnostics)





Meta-analysis diagnostics

LEGEND-T2DM Evidence Dissemination Summary

- Target (class): Semaglutide (GLP-1 Receptor Agonists)
- · Comparator (class): Glimepiride (Sulfonylureas)
- Outcome: Acute pancreatitis

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	99,708	52,939	60	1.13
Merative CCAE	20,240	9,388	14	1.49
Merative MDCD	-	-	-	-
Merative MDCR	619	278	<5	<17.97
Optum Clinformatics	7,607	3,811	8	2.10
Optum EHR	6,717	2,098	7	3.34
Veterans Affairs	1,258	883	-	0.00

How Reliable Are the Effect Estimates? (Objective diagnostics)

MDRR

	Comparator 📕 Target	📕 Before 📕 After	MDRR	 Negative control 	 Calibrated estimate
IQVIA DA German	у				
IQVIA LDP Franc	e				
IQVIA Open Claim	s Equipoise = 0.38	Max ASDM = 0.03	MDRR = 1.3	EASE = 0.08	- 0.66 (0.42 - 1.02)
Merative CCA	E Equipoise = 0.35	Max ASDM = 0.06	MDRR = 3.7	EASE = 0.06	- 0.57 (0.20 - 1.61)
Merative MDC	D				·
Merative MDCF	R Equipoise = 0.38	Max ASDM = 0.18	MDRR = 7.4	EASE = 0.37	2.54 (0.15 - 41.70)
Optum Clinformatic	s Equipoise = 0.31	Max ASDM = 0.05	MDRR = 2.4	EASE = 0.09	0.82 (0.25 - 2.68)
Optum EHF	R Equipoise = 0.25	Max ASDM = 0.08	MDRR = 2.5	EASE = 0.09	1.73 (0.56 - 5.30)
Veterans Affair	5				
	0.0 0.5 1.0 Preference score	0 0.15 0.5 1 ASDM	1 4 10 MDRR	0.5 1 2 Hazard ratio	0.5 1 2 Hazard ratio
What have we	e learned from the O	HDSI Network? (N	leta-analysis	diagnostics and	estimate)
	MDRR	 Negative control 	ol	+ Estimate	Calibrated estimate
	MDRR = 1.5	EASE = 0.04		l ² = 0	0.67 (0.47 - 0.94)
Meta-analysis					┝╼╼┥
1	4 10	0.5 1 2	0	5 1 2	0.5 1 2

Hazard ratio

Hazard ratio

Hazard ratio



Meta-analysis estimate


LEGEND-T2DM Evidence Dissemination Summary


- Target (class): Semaglutide (GLP-1 Receptor Agonists)
- Comparator (class): Glimepiride (Sulfonylureas)
- Outcome: Acute pancreatitis

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	99,708	52,939	60	1.13
Merative CCAE	20,240	9,388	14	1.49
Merative MDCD	-	-	-	-
Merative MDCR	619	278	<5	<17.97
Optum Clinformatics	7,607	3,811	8	2.10
Optum EHR	6,717	2,098	7	3.34
Veterans Affairs	1,258	883	-	0.00

How Reliable Are the Effect Estimates? (Objective diagnostics)







Next steps

- Most of you have in your hand a piece of reliable evidence that could be published and make a difference
- All of you have permission to disseminate that evidence, and explicit encouragement from the LEGEND leadership and OHDSI community to do so (just coordinate with the LEGEND team and stick to our OHDSI authorship guidelines)
- Or even better, all of you made friends today and a dream team to move forward on the opportunity together to impact the health of millions of patients



Anatomy of JACC publication

Introduction from the Editor

JACC publishes peer-reviewed articles highlighting all aspects of cardiovascular disease, including original clinical studies, experimental investigations with clear clinical relevance, state-of-the-art papers, and viewpoints.

At JACC, we value the time you spend preparing your submissions and aim to give you a rapid decision. Toward this goal, we have minimal formatting requirements on initial submissions. If your submission progresses toward publication, we may ask for more information and some specific formatting.

We are always open to suggestions about process improvements and appreciate your support of JACC.

Harlan M. Krumholz

Editor-in-Chief

Quick Submission Guide

At JACC, submit your paper your way. Authors may submit their manuscript (text, figures and tables) as a single file at www.jaccsubmit.org. This can be a Word or PDF file, in any format or layout, and figures and tables can be placed within the text. The only requirements for initial review are:

- · Please list all author names, institutional affiliations, and relationships with industry and other entities on your title page and in the online submission system (see also Relationships with Industry).
- Please consider the word and author limit for your article type (see Article Types table below); initial submissions may exceed the word limit, but our published papers, with few exceptions, need to adhere to the
 requirements.

JACC now partners with JACC: Case Reports to publish their top case reports and vignettes in a one issue per week. Authors should refer to the JACC: Case Reports instructions for authors for submission and formatting.

JACC Instructions for Authors

minimize 1. Article Types

Article Type	Description	Requirements
Original Research	Should relate to cardiovascular science and medicine that may include studies conducted in humans or analyses of human data that significantly advance the field.	Note: for initial submissions, please see the quick submission guide above; additional requirequested at revision Word Count: ≤5,000, excluding references and figure legends Author Count: Unlimited Table/Figure Count: s6 tables and/or figures , including Central Illustration Reference Count: Unlimited Central Illustration: Optional Structured Abstract ≤350 words with the headings: Background, Objectives, Methods, Results, Conclusions

Data Sharing Statement
 Follow EQUATOR Reporting Guidelines

General publication format:

- Abstract (<350 words)
- Body: (<5000 words)
 - Background
 - Methods
 - Results
 - <=6 tables/figures
 - Conclusions
- Supporting information:
 - References
 - Supplemental Materials

https://www.jaccsubmit.org/cgi-bin/main.plex?form type=display auth instructions#content



OHDSI community efforts toward supporting publications

Martijn Schuemie




Major improvements to observational research

In OHDSI, we have

- Vastly reduced time to perform observational studies (days instead of months)
- Vastly **increased the reliability of observational studies** through use of standardized analytics, objective diagnostics, and generative evidence at scale

Status quo:





What's in a (OHDSI) scientific paper?

- Background
 - What question did we seek to answer?
 - Why is it important?
 - What is already known?
- Methods
 - What data were used?
 - How were the exposures and outcomes defined?
 - What statistical analysis was performed?
 - What objective diagnostics were used?
- Results
 - Which analyses passed diagnostics?
 - What were the results?
- Discussion
 - What have we learned?
 - How does that fit with what we already knew?

Methods and Results should be **objective descriptions** of what was done and what was observed.

When using standardized analytics with standardized analysis specifications and standardized outputs, this becomes a fill-inthe-blanks exercise that can be automated.



LEGENDMed Central was a proof of concept

- Uses Rmarkdown to convert LEGEND Hypertension results to draft papers
- Select a target-comparator-outcome-database, and it would generate a PDF for you \bullet
- Still alive, but a bit buggy: <u>https://data.ohdsi.org/LegendMedCentral</u> lacksquare

Acute myocardial infarction risk in new-users of ACE inhibitors versus Angiotensin receptor blockers (ARBs) for hypertension in the CCAE database

ick B. Rvan^{a,b,d}, Seng Chan You^{a,c}, Nicole Pratt^{a,f}, David Madigan^{a,g}, George Hripcsak^{a,d}, and Marc

renefatal Information, California Los Angeles and A

mark stage 2 hypertension (W

piled on November 12, 2024.

e-scale study on the incidence of acute myocardial in- lows ten guiding principles (see Supp arction among new users of ACE inhibitors and angiotensin receptor lockers (ARBs) from 2000 to 2018 in the CCAE database. Outcomes achieve completeness and faciliate analysis of the overall distriof Interest are estimates of the hazard ratio (HR) for incident events be-bution of effect size estimates across treatments and outcomes tween comparable new users under on-treatment and intent-to-treat risk. We also generate evidence consistently by applying a systematic approach across all research questions and disseminate eviden invant subgroup interaction with the HR. We identity 773286 ACE in bitors and 228456 angiotensin receptor blockers (ARBs) patients for the aims help overcome the questionable reliable of observational re # sequences neeper toolser (AHB) patients to the specific sequences of the second sequences of the

ing using negative and positive controls to estimate and matic bias in the study design and data source oviding calibrated confidence intervals and p-values. In terms of acute cardial infarction. ACE inhibitors has a similar risk as compared to notor blockers (ARBs) [HR: 1.12, 95% confidence interv y on the incidence of acut users of ACE inhibitors and angioten orn 2000 to 2018 in the CCAE database. Out ates of the hazard ratio (HR) for incident events w users under on-treatment and intent-to-treat risk ptions. Secondary analyses entertain possible clinical elevant subgroup interaction with the HR. We identify 773286 ACE inibitors and 228456 angiotensin receptor blockers (ARBs) patients for the ment design, totaling 585438 and 199155 patient-years of obser tion, and 1596 and 468 events respectively. We control for measured ensity score trimming and stratification or matchenaity score model that includes all me atic bias in the study design and data source ce intervals and p-values. In terms of acute bitors has a similar risk as compared to ers (ARBs) [HR: 1.12, 95% confidence interval

et al.~provide a sy st. ac.~provide a systematic review of randomized controlled trial examining comparative benefits and harms of various antihype tensives as first-line therapy (Reboussin et al., 2017). Furthe observational study can help refine first-line therapy recommendation of the statement of the statem arge-scale Evidence Generation and Evaluation in a Net s (LEGEND) project aims to generate reliable ts of medical interventions using observational apport clinical decision making. LEGEND fol-

as well as enn

time users of ACEIs or ARBs, and who have a diagnosi Worldwide. hypertension stands as a leading cause of mortality n on or prior to treatment initation. We require that asing prevalence over the last two decades (Forou far et al. 2017). The 2017 American College of Cardiology (ACC) iation (AHA) clinical practice guid ured in a healthcare setting; systolic BP between 120 - 139 mml r diastolic BP between 80 - 89 mmHg characterize stage 1 hyp ension, and systolic BP > 140 mmHg or diastolic BP > 90 mmH tion. We begin the outcome risk window 1 da ton et al., 2018). Elevated BF end. First, we end the outcome time-at-risk window ontribute to approximately half of all stroke and ischemic hear on of conti lisease deaths and 13% of all forms of deaths globally (WHC and, second, we end the outco 009). While antihypertensive therapies carry well-established benefits in reducing BP and the risk of major cardiovascular even the health benefits and drug safety concerns of any one class o nsive drugs relative to other classes as first-line the emains debatable. Part of this debate arises from a paucity of larg remains debatable. Part of this debate arises from a paucity of large randomized controlled trials and observational studies providing head-to-head comparisons between all pairs of individual drugs and drug classes. One notable counter-example is the Antihyper-tensive and Lipdi-Jowening Treatment to Prevent Heart Attack Trial (ALLHAT) (ALLHAT) Officers and Coordinators for the ALLHAT Col-homanic Desar Control Antibus Attack and the ALLHAT Colale analytics achieved through the Cyclops R package et al. 2013) We use propensity scores (PSs) - estimate aborative Research Group, 2002) that randomized 33,357 patient o receive either amlodipine (a dihydropyridine calcium channe blocker), chlorthalidone (a thiazide or thiazide-like diuertic) or r potential measured confoudning and improve bal-n the target (ACEIs) and comparator (ARBs) cohorts and Rubin, 1983). We use an expansive PS model sinopril (an angiotensin converting enzyme inhibitor). How ALLHAT employed only a single drug representative per class and did not include several other important antibyne s all available patient demographics, drug, condition covariates generated through the FeatureExtraction

s those from the 2017 ACC/AHA guidelines and the 2018 ean Society of Cardiology (ESC) and European Society o

ns et al., 2018)

ion (ESH) Guidelines for the management of arteria


ACEIs: n = 8883713 APIDs: n = 5217548 area. We conduct a new-user cohort study comparing new ACEIs with new users of ARBs in the Truven Health Mar-Commercial Claims and Encounters Database (CCAE) e encoded in the Observational Medical Outcomes Part-ACEIs: n = \$10667 ARDs: n = 100205 common data model (CDM) version 5 (Hripcsal hage et al., 2012; Ryan et al., 2013). The CCAI from individuals enrolled in United States employe ance health plans. The data includes adjudicate ACEIs: n = 0 ARBs: n = 0 e claims (e.g. inpatient, outpatient, and outpatie ent data from large employers an wide private healthcare coverage to employ nts. Additionally, it captures labor ing duplicate s to first cohort ACEIs: n = 0 ARBs: n = 0 and dependents: Additionary, it captures another additionary abset of the covered lives. This administrative claims fundes a variety of fee-for-service, preferred provider is, and capitated health plans. The study period spans 12-31, 2000-12-31 to 2018-03-31, 2018-03-31. ACEh: n = 2529 ARBs: n = 471 r outcome n. This study follows a retrospective, observational cohort design (Ryan et al., 2013). We include patient ACEIs: n = 3228 ARRs: n = 1075 at least 1 days at risk ation in the database for at les Study population: ACEIs: n = 773286 ABBs: n = 725455 details, include concept codes, are provide aformation. The outcome of interest is acu ion and consider two design choices to defin nuous drug exposure, analogous to a nt is no longer observable in the databas sured and systematic sources Residual study bias from un is that have fewer than 30 days gap between can exist in observational studies after controlling for measured confounding (Schuemie et al., 2014, 2016). To estimate such esidual bias, we conduct negative control outcome experime s. We conduct our cohort study using the openwith 292 negative control out comes identified through a data HDSI CohortMethod R package (Schuemie et al., 2018c), rich algorithm (Voss et al., 2017). We fit the negative contr pirical null distribution that ch we additionally calibrate all HR estimates, their 95% confider intervals (CIs) and the p-value to reject the null hypothesis of no differential effect (HR = 1). Empirical calibration serves as an mportant diagnostic tool to evaluate if residual systematic erro s sufficient to cast doubt on the accuracy of the unknown effect temie et al., 2018d) instead of a prespecified set of ted confounders. We perform PS stratification o atching and then estimate comparative ACEIs-y ising a Cox prope tional hazards mode ions are provided in the and covariate balance study subject e CCAE database under the on-treatm study subjects from the CCAE datab We present PS and

with stratification design. We augment these counts with coh-

Fir and APP

ding control, and provide HR

Exposed: ACEIs: n = 10173421 ARBs: n = 5547855



_						model." Transactions on Modeling and Computer Simulation, 23, 10.
2.8	2.9	0.00	2.8	3.0	10.0	allelization of serial inference algorithms for a complex generalized line
17.6	18.2	4.02	17.6	18.3	-0.02	Suchard M, Simpson S, Zorych I, Ryan P, Madigan D (2013). "Massive pr
24.6	23.8	0.02	24.5	24.9	-0.01	
1.5	1.7	-0.02	1.5	5.6	-0.01	Generating Features for a Cohort. R package version 2.1.5.
15.6	10.0	0.58	14.5	14.6	0.00	Schuemie MJ, Suchard MA, Ryan PB, Reps J (2018d). FeatureExtraction
18.1	19.2	-0.03	18.4	18.5	0.00	2.5.1.
14.1	15.6	-0.04	14.4	14.6	0.00	method with large scale propensity and outcome models. R package version
	0.0	0.00	0.0	1.1	0.00	Schuemie MJ, Suchard MA, Ryan PB (2018c). CohortMethod: New-user coho
8.5	0.5	0.00	0.5	6.5	0.00	p-values." Statistics in medicine, 33(2), 209-218.
2.3	2.9	0.02	3.2	2.3	0.00	
0.4	0.5	-0.01	0.4	0.4	10.01	preting observational studies: why empirical calibration is needed to corre
1.4	1.5	-0.01	14	1.5	0.00	Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D (2014). "Inte
6.2 24.3	5.9	0.01	6.1 24.0	8.3	-0.01	Sciences, p. 201708282.
17.7	17.2	0.01	17.6	17.8	-0.01	in observational healthcare data." Proceedings of the National Academy
48.8	50.1	-0.05	49.0	48.6	-0.01	confidence interval calibration for population-level effect estimation stude
1.5	2.0	- 30	03	2.5	0.00	Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA (2018b). "Empiric
8.5	0.1	0.00	0.1	8.5	0.00	
8.5	0.1	0.00	0.1	8.1	0.00	Medicine, 35(22), 3883–3888.
6.2	0.2	0.00	0.2	6.2	0.00	bust empirical calibration of p-values using observational data." Statistics
8.7	0.9	-0.02	0.7	0.8	10.01	Schuemie MJ, Hripcsak G, Rvan PB, Madigan D, Suchard MA (2016). "R
42	4.8	0.00	4.3	4.4	0.00	calibration." Philosophical Transactions of the Royal Society A, 376, 2017035
6.2	0.2	0.00	0.2	82	0.00	reproducibility by using high-throughput observational studies with empiric
8.5	0.5	0.00	0.5	0.6	-0.01	Schuemie M, Ryan P, Hripcsak G, Madigan D, Suchard M (2018a). "Improvin
1.0	1.1	0.00	1.0	1.0	0.00	identification and analysis system." Drug Safety, 36(1), 59-72.
41	45	-0.02	4.2	43	0.00	performance of a new user cohort method: lessons for developing a ris
1.7	1.0	-0.01	1.8	1.8	0.00	Rvan PB. Schuemie MJ. Gruber S. Zorvoh I. Madigan D (2013). "Empiric
0.5	0.5	-0.01	0.5	0.5	0.00	observational studies for causal effects." Biometrika, 70(1), 41-55.
8.0	11.2	-0.07	9.5	8.2	-0.01	Rosenbaum PR, Rubin DB (1983). "The central role of the propensity score
17	1.5	0.02	17	1.6	0.00	Journal of the American College of Cardiology, p. 24428.
84	0.5	-0.01	0.4	8.4	0.00	
						ology/American Heart Association Task Force on Clinical Practice Guideline
15.5	16.6	-0.00	15.8	15.8	0.00	high blood pressure in adults: a report of the American College of Car
8.4	0.4	0.00	0.4	0.4	0.01	guideline for the prevention, detection, evaluation, and management
8.5	0.3	0.00	0.3	8.3	0.00	for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PC#
83	0.1	0.01	0.1	8.5	0.00	EPR, Polonsky T, Thompson-Paul AM, Vupputuri S (2017). "Systematic revie
1.8	0.9	-0.01	0.8	1.8	0.00	Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Mil
5.5	1.2	-0.01	1.1	1.5	0.00	
1.8	1.8	-0.01	1.0	1.8	0.00	American Medical Informatics Association, 19, 54–60.
11.3	12.2	-0.03	11.5	11.6	0.00	common data model for active safety surveillance research." Journal of t
8.5	7.3	0.04	8.3	8.2	0.00	Overhage J, Ryan P, Reich C, Hartzema A, Stang P (2012). "Validation of
1.2	0.2	0.00	0.2	6.2	0.00	in health technology and informatics, 216, 574-578.
105.0	100.0	0.00	120.0	108.8	-0.01	Informatics (OHDSI): Opportunities for Observational Researchers." Studi
82	0.2	0.01	0.2	8.2 37.1	0.00	Wong I, Rijnbeek P, et al. (2015). "Observational Health Data Sciences a
17	2.0	4.02	1.8	1.8	0.00	Hripcsak G, Duke J, Shah N, Reich C, Huser V, Schuemie M, Suchard M, Park
7.8	8.3	-0.02	7.9	7.9	0.00	
16.3	13.0	0.12	17.4	17.5	0.00	Journal of the American Medical Association, 317(2), 165–182.
2.4	6.5	0.00	0.1	2.5	0.00	sion and systolic blood pressure of at least 110 to 115 mm Hg. 1990-2011
6.3	0.3	0.00	0.3	6.3	0.00	Estep K. Abate KH. Akinverniu TF. et al. (2017). "Global burden of hyperte

C MDRB

72 estimates 56.9% of CIs include 4

· Risk Scores (Charlson comorbidity index

Massive pa reralized linear 7, 23, 10. Voss EA. Boyce RD, Ryan PB, van der Lei J, Rjinbeek PR, Schuemie MJ (2017)

We exclude all covariates that occur in fewer than 0.1% o

atients within the target and comparator cohorts prior to model

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group

(2002). "Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihvoortensive and loid-lowering treatment to prevent heart attack trial

(ALL MAT)* Journal of the American Medical Accordance 988, 2081-2007

a JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH (2016). "A

S. Waller PC, Davis S (2001). "Use of proportional reporting ra Rej for signal generative formation for a second se

rtional reporting ratio

35

fitting for computational efficiency.

ustin PC (2009). "Balance diagnostics for ci

edin J Li X (2013) 1C/

" Scientific date 3, 16002

Rs) for signal generation from spontaneous ad rmsconnidemiology and Drug Safety, 10(6).



LEGENDMed Central Methods sections

- Pulled in a description of the database
- Referred to the protocol for exposure and outcome definitions
- Study design was fixed (it's a LEGEND study), so used standard text
- We did not yet use objective diagnostics at the time

OHDSI cohort definitions can be converted to human-readable text

Could modify to reflect design choices

such as those from the 2017 ACC/AHA guidelines and the 2018 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension(Williams et al., 2018).

Methods

Data source. We conduct a new-user cohort study comparing new users of ACEIs with new users of ARBs in the Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) database encoded in the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) version 5 (Hripcsak et al., 2015; Overhage et al., 2012; Ryan et al., 2013). The CCAE represent data from individuals enrolled in United States employersponsored insurance health plans. The data includes adjudicated health insurance claims (e.g. inpatient, outpatient, and outpatient pharmacy) as well as enrollment data from large employers and health plans who provide private healthcare coverage to employees. their spouses, and dependents. Additionally, it captures laboratory tests for a subset of the covered lives. This administrative claims database includes a variety of fee-for-service, preferred provider organizations, and capitated health plans. The study period spans from 2000-12-31, 2000-12-31 to 2018-03-31, 2018-03-31.

Study design. This study follows a retrospective, observational. comparative cohort design (Ryan et al., 2013) . We include patients who are first time users of ACEIs or ARBs, and who have a diagnosis of hypertension on or prior to treatment initation. We require that patients have continuous observation in the database for at least 365 days prior to treatment initiation. We exclude patients with prior acute myocardial infarction events and less than 1 day at risk. Links to full cohort details, include concept codes, are provided in the Supporting Information. The outcome of interest is acute myocardial infarction. We begin the outcome risk window 1 day after treatment initation and consider two design choices to define the window end. First, we end the outcome time-at-risk window at first cessation of continuous drug exposure, analogous to an on-treatment design and, second, we end the outcome time-at-risk window when the patient is no longer observable in the database, analogous to an intent-to-treat design. Continuous drug exposures are constructed from the available longitudinal data by considering sequential prescriptions that have fewer than 30 days gap between prescriptions.

Statistical analysis. We conduct our cohort study using the opensource OHDSI CohortMethod R package (Schuemie et al., 2018c), with large-scale analytics achieved through the Cyclops R package (Suchard et al., 2013). We use propensity scores (PSs) - estimates of treatment exposure probability conditional on pre-treatment baseline features in the one year prior to treatment initiation to control for potential measured confoudning and improve balance between the target (ACEIs) and comparator (ARBs) cohorts (Rosenbaum and Rubin, 1983). We use an expansive PS model that includes all available patient demographics, drug, condition and procedure covariates generated through the FeatureExtraction R package (Schuemie et al., 2018d) instead of a prespecified set of investigator-selected confounders. We perform PS stratification or variable-ratio matching and then estimate comparative ACEIs-vs-ARBs hazard ratios (HRs) using a Cox proportional hazards model. Detailed covariate and methods informations are provided in the Supporting Information. We present PS and covariate balance metrics to assess successful confounding control, and provide HR

2




Fig. 1. Attrition diagram for selecting new-users of ACEIs and ARBs from the CCAE database.

estimates and Kaplan-Meier survival plots for the outcome of acute myocardial infarction.

Residual study bias from unmeasured and systematic sources can exist in observational studies after controlling for measured confounding (Schuemie et al., 2014, 2016). To estimate such residual bias, we conduct negative control outcome experiments with 292 negative control outcomes identified through a datarich algorithm (Voss et al., 2017). We fit the negative control estimates to an empirical null distribution that characterizes the study residual bias and is an important artifact from which to assess the study design (Schuemie et al., 2018a). Using the empirical null distribution and synthetic positive controls (Schuemie et al., 2018b) , we additionally calibrate all HR estimates, their 95% confidence intervals (CIs) and the p-value to reject the null hypothesis of no differential effect (HR = 1). Empirical calibration serves as an important diagnostic tool to evaluate if residual systematic error is sufficient to cast doubt on the accuracy of the unknown effect estimate.

Results

Population characteristics. Figure 1 diagrams the inclusion of study subjects from the CCAE database under the on-treatment with stratification design. We augment these counts with cohort




LEGENDMed Central Results sections

- Pulled figures and tables from the results database
 - Standard set of results artifacts, including 'Table 1'
- Use simple logic to modify text
 - E.g. if max(SDM) > 0.1, would call this out
- Did not use blinding when diagnostics failed

Nowadays we'd review all diagnostics and blind when appropriate

Could re-use a lot of the one-pager we printed for the closing session here!






Fig. 2. Preference score distribution for ACEIs and ARBs new-users. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. A higher overlap indicates that subjects in the two populations are more similar in terms of their predicted probability of receiving one treatment over the other.




Fig. 3. Patient characteristics balance before and after stratification. As a rule-of-thum, all values < 0.1 is generall considered well-balance (Austin, 2009).

sizes we identify for the remaining designs in Table 1. This table also reports total patient follow-up time, numbers of acute myocardial infarction events these patients experience and unadjusted incidence rates. Table 2 compares base-line characteristics between patient cohorts.

Patient characteristics balance. Figure 2 plots the preference score distributions, re-scalings of PS estimates to adjust for differential treatment prevalences, for patients treated with ACEIs and ARBs. We assess characteristics balance achieved through PS adjustment by comparing all characteristics' standardized difference (StdDiff) between treatment group means before and after PS trimming and stratification (Table 2). Figure 3 plots StdDiff for all 55518 base-line patient features that serve as input for the PS model. Before stratification, 23 features have a StdDiff > 0.1. After stratification, the count is 0.

Outcome assessment. Table 3 details the time to first acute myocardial infarction or censoring distributions for patients in the ACEIs and ARBs cohorts. We report in Table 4 estimated HRs comparing ACEIs to ARBs for the on-treatment and intent-to-treat

Fig. 4. Kapian Meler plot of acute myocardial infarction-free survival. This plot is adjusted for the propensity score stratification: the ACEIs curve shows the actual observed survival. The ARBs curve applies reweighting to approximate the counterfactual of what ACEIs survival would look like had the ACEIs ochort been exposed to ARBs instead. The shaded area denotes the 95% CI.

designs with stratification or matching. Figure 4 plots Kaplan-Meier survival curves for patients under the intent-to-treat design.

Warning: Using `size` aesthetic for lines was deprecated

i Please use `linewidth` instead.

This warning is displayed once every 8 hours.

Call `lifecycle::last_lifecycle_warnings()` to see where ## generated.

Residual systematic error. In the absense of bias, we expect 95% of negative and positive control estimate 95% confidence intervals to include their presumed HR. In the case of negative controls, the presumed HR = 1. Figure 5 describes the negative and positive control estimates under the on-treatment with PS stratification design. Before calibration, negative and positive controls demonstrate poor coverage. After calibration, controls demonstrate acceptable coverage.

Conclusions

We find that ACEIs has a similar risk of acute myocardial infarction as compared to ARBs within the population that the CCAE represents.

Supporting Information

Here we enumerate the guiding principles of LEGEND and provide linking details on study cohorts and design.

LEGEND principles.

Evidence will be generated at large-scale.

- Dissemination of the evidence will not depend on the estimated effects.
- Evidence will be generated using a pre-specified analysis design.
- Evidence will be generated by consistently applying a systematic approach across all research questions.

Schuernie et al.




What about other sections?

- Background
 - What question did we seek to answer?
 - Why is it important?
 - What is already known?
- Methods
 - What data were used?
 - How were the exposures and outcomes defined?
 - What statistical analysis was performed?
 - What objective diagnostics were used?
- Results
 - Which analyses passed diagnostics?
 - What were the results?
- Discussion
 - What have we learned?
 - How does that fit with what we already knew?

Background section is primarily a **synthesis of the context of the research question**

Large language models could nowadays help with this





Draft background section writer using generative AI

- Proof-of-concept suggests this is feasible
- Needs thorough evaluation
 - Initial results to reproduce background sections in PubMed Central show large variability in background sections
 - Will require human review
- Several methodological questions remain open
 - E.g. Should we pull in full-text articles?
- Non-trivial computational costs



Conclusions

- Writing papers has become the bottleneck in generating and disseminating evidence
- There are opportunities for increasing efficiency
 - Methods and Results: We could create a template that is filled in with (standardized) analysis specifications and results
 - Background section: generative AI could help here, but more research is needed
- These are great opportunities for the OHDSI community!



Join the Journey of the Evidence Translation Workgroup

Nicole Pratt




Flashback...OHDSI APAC 2023

Our ingredients are data

Our craft is science


Our brew is evidence

Our duty is to share it





What Can OHDSI Achieve Together in 2024? (Jan. 8 Community Call)






OHDSI Symposium 2023

https://www.youtube.com/watch? v=jNrCMyXkg9c MORE VIDEOS

12:52 / 45:24

"I think as a community we have done an amazing job in standardization, standardization through a common data model, standardization of tools that will execute this data model, and it makes these types of studies much easier...

We have **abjectly failed** on the next step, and that's providing standardized tools that allow us to synthesize and then deliver this evidence in a way that's actionable not only in our community, but across healthcare and clinical practice in general."



CC

"Making evidence actionable" Patrick Ryan What can OHDSI Achieve Together in 2024 Jan 9 https://ohdsi.org/community-calls/



How can OHDSI *improve the use and uptake* of the real world evidence we produce so that it is "actionable" and can be readily consumed to aid in decision making?





We need everyone at the table to not only consume the evidence but also to **set the menu!**





How can OHDSI help [you] by generating evidence for the *questions* that matter to [you]?

What else can OHDSI do to *build trust* that the evidence we provide is reliable and can be used in decision making?

How can OHDSI *improve understanding* about real world evidence we produce so that it can be used in decision making?

New OHDSI Work Group: Evidence Translation

CMAJ

Defining knowledge translation

Sharon E. Straus MD MSc, Jacqueline Tetroe MA, Ian Graham PhD

When the cannot pick up a magazine or surf the Internet without facing reminders of the challenges to health care and the "sorry state" of health systems.¹ All health care systems are faced with the challenges of improving quality of care and reducing the risk of adverse events.² Globally, health systems fail to use evidence optimally. The result is inefficiency and a reduction in both quantity and quality of life.^{3,4} For example, McGlynn and colleagues⁵ found that adults in the United States received less than 55% of recommended care. Providing evidence from clinical research (e.g., through publication in journals) is necessary but not enough for the provision of optimal care. Recognition of this issue has created interest in knowledge

translation, also known as KT, which we define as the methods for closing the gaps from knowledge to practice. In this series of articles, we will provide a framework for implement-

ing knowledge for clinicians, managers and policy-makers.

Key points


 Gaps between evidence and decision-making occur at all levels of health care, including those of patients, health care professionals and policy-makers.

Review

- Knowledge translation involves using high-quality knowledge in processes of decision-making.
- The knowledge-to-action framework provides a model for the promotion of the application of research and the process of knowledge translation.

Knowledge creation (i.e., primary research), knowledge distillation (i.e., the creation of systematic reviews and guidelines) and knowledge dissemination (i.e., appearances in journals and presentations) are not enough on their own to ensure the use of knowledge in decision-making.

We should also clarify what knowledge translation isn't.



🗘 ktdrr

🍁 cihr-irsc.gc.ca

Senart, tantos ingramant interventiges Access Berners La knowledge use

🗘 ktdrr

R

R⁶ ResearchGate

Knowledge-To-Action Cycle ...

Encodedpe Priloty Recolution Southern

ACTION CTC

Knowledge Translation: Introduction...

ge Translation (KT) M...

- 4 -

Intervention

\$

Assess Barriers t Knowledge

ţ

Adapt

O

Adapt

KNOWLEDGE TO ACTION PROCESS Line:

Evaluate Outcomes

ions KT, Research

Knowledge Translation: Introduction...



Itelateu searenes

knowledge translation

research knowledge

knowledge translation

knowledge translation

Evaluate Outcomes

Sustain Knowledge Use

Sustain knowledge use

strategies

translation

process -

healthcare

Cn

💎 Semantic Scholar

Select, salary industrial industrial industrial barriers to barrie

🗘 ktdrr

K

Knowledge Translation

month and attacks

🝁 cihr-irsc.gc.ca

Knowledge translation: putting the ...

Hirawhelipe Impuny

Knowledge Byrthesis

ACTION CYCL

Select, Tailor, Implement Interventions

Attentions Attention bio Knowledge Ute Attent Knowledge to Local Context


Monitor Knowledge Use


Knowledge Inquiry Knowledge Synthesis

Tools/

F-Words* KT Strat


■ Q knowledge translation framework








: ×



Source: Cochrane Knowledge Translation Framework April 2017







Producing the Evidence

• Prioritisation Identify the questions that are important to different stakeholders

• Co-production Identify opportunities for stakeholder involvement throughout the evidence generation pipeline to ensure alignment of needs

Objectives

capacity in end-users finding and using evidence Set the table Make it palatable Are they eating it? Create an appetite **Consumer forums** Create user friendly Create impact stories, Create evidence briefs, findable, open-source diffusion of evidence, **Engagement with** lay summaries tools "evidence libraries" regulators audiences reached Key Results

10

Making it accessible

- Packaging, push and support to implementation Identify methods and pathways for evidence dissemination
- Facilitating pull Making evidence findable accessible and developing

Making evidence palatable

• Exchange Develop consumable evidence communications that are tailored to the needs of different stakeholders. Develop strategic partnerships, forums to exchange ideas

Measuring the uptake

• *Monitoring* the uptake, reach and impact of OHDSI research into policy and/or practice



Next Steps

- Join the work group: WG sign up for the community to Teams channel
- Set up a schedule of Meetings
- Set Objectives & Key Result (OKR)
- **Purpose**: The Evidence Translation workgroup exists to promote and facilitate the dissemination and uptake of evidence generated by the OHDSI community into all aspects of health care decision-making.